Myriad Genetics Inc (MYGN)
Receivables turnover
Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 817,300 | 794,900 | 766,400 | 745,400 | 731,500 | 696,200 | 691,900 | 675,200 | 820,600 | 831,200 | 839,900 | 846,300 | 666,200 | 590,100 | 564,400 | 586,600 | 627,900 | 750,000 | 801,700 | 822,500 |
Receivables | US$ in thousands | 125,700 | 117,800 | 118,100 | 114,300 | 115,200 | 111,700 | 119,100 | 101,600 | 102,200 | 109,800 | 101,700 | 91,300 | 93,600 | 94,800 | 96,500 | 87,100 | 71,000 | 105,000 | 121,800 | 121,800 |
Receivables turnover | 6.50 | 6.75 | 6.49 | 6.52 | 6.35 | 6.23 | 5.81 | 6.65 | 8.03 | 7.57 | 8.26 | 9.27 | 7.12 | 6.22 | 5.85 | 6.73 | 8.84 | 7.14 | 6.58 | 6.75 |
September 30, 2024 calculation
Receivables turnover = Revenue (ttm) ÷ Receivables
= $817,300K ÷ $125,700K
= 6.50
The receivables turnover ratio for Myriad Genetics Inc has fluctuated over the past several quarters. The ratio measures how efficiently the company is collecting on its accounts receivable. A higher ratio indicates that the company is collecting receivables more quickly.
The trend in Myriad Genetics Inc's receivables turnover ratio shows some variability, with values ranging from 5.81 to 9.27 over the past five quarters. The company generally maintained a relatively stable turnover ratio between 6.50 and 6.75 in the most recent quarters, indicating a consistent ability to convert its accounts receivable into cash.
The significant increase in receivables turnover to 9.27 in December 2021 from previous quarters may suggest a more efficient collection process during that period. However, the ratio decreased in subsequent quarters but remained above the levels observed in earlier years.
Overall, Myriad Genetics Inc's receivables turnover ratio has shown some fluctuations but generally reflects a satisfactory level of efficiency in collecting on its accounts receivable in recent quarters. Continued monitoring of this ratio will be important to assess the company's ongoing ability to manage its receivables effectively.
Peer comparison
Sep 30, 2024